United Therapeutics (UTHR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$487.61-0.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Research Workspace
Put UTHR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Deliver durable double-digit revenue growth: rev -2.0% vs 11% target.
View ThesisRevenue growth is slowing — up about 2% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 10%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskUnited Therapeutics must deliver durable double-digit revenue growth to justify its current price. Recent revenue declined 2% year over year, missing the 11% growth target. The stock trades at 17× P/E, below the 22× peer median, indicating modest growth expectations. If UTHR cuts guidance on the next call, it could negatively impact the stock. Peer multiples imply a price about 14% above where it trades. This read is provisional.
Trailing returns as of 2026-09-04. UTHR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering UTHR (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare UTHR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| UTHR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put UTHR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance regulatory approvals for ralinepag and nebulized Tyvaso in new indicati…
FDA acceptance supports regulatory approval for Tyvaso.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance regulatory approvals for ralinepag and nebulized Tyvaso in new indicati…
New data supports regulatory approvals for ralinepag and Tyvaso.
Advances: Advance regulatory approvals for ralinepag and nebulized Tyvaso in new indicati…
FDA acceptance is a significant step for ralinepag approval.
Advances: Advance regulatory approvals for ralinepag and nebulized Tyvaso in new indicati…
FDA acceptance supports regulatory approval for ralinepag.
Advances: Advance ralinepag development and regulatory submission
Strong pipeline progress supports ralinepag development.
Advances: Advance ralinepag development and regulatory submission
Potential approvals for ralinepag support product development goals.
Threatens: Deliver durable double-digit revenue growth
Revenue miss impacts growth objective.
Advances: Deliver durable double-digit revenue growth
Positive outlook on Tyvaso franchise supports revenue growth objective.
